Home/Pipeline/Schizophrenia Program

Schizophrenia Program

Schizophrenia

DiscoveryActive

Key Facts

Indication

Schizophrenia

Phase

Discovery

Status

Active

Company

Herophilus

About Herophilus

Herophilus is a private, pre-clinical stage biotech leveraging a proprietary platform of human brain organoids, high-throughput biology, and AI/ML to de-risk and accelerate CNS drug discovery. The company has established a pipeline targeting high-need neurological and psychiatric conditions, including Rett syndrome, Alzheimer's disease, and schizophrenia, starting from a patient-derived biobank. By generating deep phenotypic data from physiologically relevant human models, Herophilus aims to identify novel drug candidates with a greater probability of clinical success.

View full company profile

Therapeutic Areas

Neurology Psychiatry

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active